$RNAZ News
Last published 2w ago
- 2w agoRNAZTransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology PortfolioPR NewswireLead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatmentTransCode will evaluate strategic alternatives including licensing arrangements,
- 2w agoRNAZTransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026PR NewswirePoster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumorsBOSTON, Oct. 26, 2026 /PRNewswire/ --
- 3w agoRNAZTransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026PR NewswirePoster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumorsBOSTON, Oct. 19, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage
- 4w agoNTRARNAZNatera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerBusiness WireTransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc.
- 1mo agoRNAZTransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-UpPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high ...
- 1mo agoRNAZTransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologyPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced...
- 1mo agoRNAZEarnings Call - TRANSCODE THERAPEUTICS INCEarnings Call TranscriptsHello, this is Craig Bralsford with Red Ship Companies. Thank you for joining today's event with Transcode Therapeutics, which trades on the NASDAQ under the ticker RNAZ. Joining us today is Philippe Calais, Chairman and
- 2mo agoRNAZTransCode Therapeutics Announces Leadership TransitionPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced...
- 2mo agoRNAZTransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone MetastasisPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high ...
- 5mo agoRNAZTransCode Therapeutics to Host R&D Webcast on June 18, 2026PR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and...
- 5mo agoRNAZTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic CancerPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced...
- 5mo agoRNAZTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced...
- 6mo agoRNAZTransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State UniversityPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk...
- 7mo agoRNAZTransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028PR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high...
- 8mo agoRNAZTransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer PatientsPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced...
- 8mo agoRNAZTransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further DevelopmentPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk...
- 9mo agoRNAZTransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138PR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment...
- 10mo agoRNAZTransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in GlioblastomaPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk...
- 10mo agoRNAZTransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of DirectorsPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced...
- 11mo agoRNAZTransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trialPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate ...
- 11mo agoRNAZTransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development OfficerPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy,...
- 1y agoRNAZTransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMOPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of...
- 1y agoRNAZTransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology companyPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire...
- 1y agoRNAZTransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory BoardPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer,...
- 1y agoRNAZTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities ReportedPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer...
- 1y agoRNAZTransCode Therapeutics Announces 1-for-28 Reverse Stock SplitPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer...
- 1y agoRNAZTransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic CancerPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special MeetingPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer...
- 1y agoRNAZTransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138PR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics, Inc. Announces Closing of Registered Direct OfferingPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer...
- 1y agoRNAZTransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical TrialPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics, Inc. Announces Results of Special MeetingPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer...
- 1y agoRNAZTransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical TrialPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special MeetingPR NewswireTransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer...
- 1y agoRNAZTransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical TrialPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical TrialPR NewswireTransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
- 1y agoRNAZTransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock SplitGlobeNewswireBOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA
- 1y agoRNAZTransCode Therapeutics, Inc. Announces $8 Million Private PlacementGlobeNewswireBOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has
- 1y agoRNAZTransCode Therapeutics Announces 1-for-33 Reverse Stock SplitGlobeNewswireBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA
- 1y agoRNAZTransCode Therapeutics Open Letter to ShareholdersGlobeNewswireBOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholders, At our upcoming
- 2y agoRNAZTransCode Therapeutics Announces Nasdaq Extension to Regain ComplianceGlobeNewswireBOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received
- 2y agoRNAZTransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety DataGlobeNewswireThe clinical trial Safety Review Committee (SRC) approved opening of Cohort 2 after review of safety data from the three patients comprising Cohort 1No significant safety or dose limiting toxicities have been reported in
- 2y agoRNAZTransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted TechnologyGlobeNewswirePatients currently remain on study for continued treatment with TTX-MC138 No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleotide conjugated to TransCode's proprietary TTX
- 2y agoRNAZTransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic CandidateGlobeNewswireTwo patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancerTTX-MC138 is an antisense oligonucleotide conjugated to
- 2y agoRNAZTransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic CancerGlobeNewswireBOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, in collaboration with Michigan State
- 2y agoRNAZTransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateGlobeNewswireBOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been
- 2y agoRNAZTransCode Therapeutics Announces Phase 1 Clinical Trial InitiationGlobeNewswireTwo clinical trial sites activatedPatient enrollment expected this quarterTrial designed to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- TransCode